Last update 21 Nov 2024

Daptomycin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
CUBICIN, Cubicin Iv, Daptomycin (JAN/USAN/INN)
+ [12]
Target-
Mechanism
Cell membrane function inhibitors
Originator Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

Structure

Molecular FormulaC72H101N17O26
InChIKeyDOAKLVKFURWEDJ-QCMAZARJSA-N
CAS Registry103060-53-3

External Link

KEGGWikiATCDrug Bank
D01080Daptomycin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sepsis
JP
01 Jul 2011
Bacteremia
CN
02 Sep 2009
Bacterial Infections
CN
02 Sep 2009
Staphylococcal Infections
CN
02 Sep 2009
Complicated skin and soft tissue infection
IS
19 Jan 2006
Complicated skin and soft tissue infection
LI
19 Jan 2006
Complicated skin and soft tissue infection
NO
19 Jan 2006
Complicated skin and soft tissue infection
EU
19 Jan 2006
Right sided infective endocarditis
EU
19 Jan 2006
Right sided infective endocarditis
IS
19 Jan 2006
Right sided infective endocarditis
NO
19 Jan 2006
Right sided infective endocarditis
LI
19 Jan 2006
Staphylococcus aureus bacteraemia
IS
19 Jan 2006
Staphylococcus aureus bacteraemia
LI
19 Jan 2006
Staphylococcus aureus bacteraemia
NO
19 Jan 2006
Staphylococcus aureus bacteraemia
EU
19 Jan 2006
Staphylococcus Aureus Infections
NO
19 Jan 2006
Staphylococcus Aureus Infections
LI
19 Jan 2006
Staphylococcus Aureus Infections
IS
19 Jan 2006
Staphylococcus Aureus Infections
EU
19 Jan 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Right sided infective endocarditisPhase 2
US
30 Nov 2010
Gram-Positive Bacterial InfectionsPhase 2--19 Dec 2002
Endocarditis, BacterialPhase 2--01 Mar 2002
Staphylococcus aureus bacteraemiaPhase 2--01 Mar 2002
Community-acquired bacterial pneumoniaPhase 2--31 Oct 2000
Gram-Positive Bacterial InfectionsDiscovery--19 Dec 2002
Endocarditis, BacterialDiscovery--01 Mar 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
12
numzeumdbg(zgceqqveyw) = zbkytequci vomneelpjs (dtokpntngk, 123.5)
Positive
04 Nov 2024
numzeumdbg(zgceqqveyw) = scwnuaeacj vomneelpjs (dtokpntngk, 102.5)
Phase 2
200
(Dalbavancin)
jkxfzcvjmj(dmwvsxmhvv): Pr(Better DOOR in dalbavancin arm) = 47.70 (95% CI, 39.84 - 55.68)
-
22 Oct 2024
(Standard of Care)
Not Applicable
-
zjmhkvdmvt(siduilwokw) = This patient has 2 risk factors, which are the duration of treatment of more than 14 days and the high Charlson Comorbidity Index of 9. Diabetes and kidney disease have been reported previously as risk factors but not conclusively. Mainstay treatment is to stop the offending drug and start on steroids. Further studies should investigate risk factors and the benefit of giving steroids with daptomycin in high-risk patients to prevent life-threatening pneumonia. qiikjyblwk (tkntrcjyzm )
-
19 May 2024
Not Applicable
-
cikyuedhcd(bcsrxftlke) = Eosinophilic pleural effusion co-occurred following prolonged daptomycin therapy ramfpwkxqe (phresvsjze )
-
19 May 2024
Not Applicable
-
ngyxrzqnxt(mfmhpwwivr) = A rapid response was called for worsening acute hypoxic respiratory failure with increasing high flow nasal cannula requirements despite aggressive diuresis. eaezajxpqr (kilzrmclbs )
-
19 May 2024
Not Applicable
-
izcgahfhbs(ssmripcswd) = Acute eosinophilic pneumonia (AEP) is an uncommon, potentially fatal lung disease. Antibiotics are a possible cause of drug induced eosinophilic lung disease. gcerfdrahh (nzmfioifmj )
-
19 May 2024
Not Applicable
-
qlgyhejanp(tqxkiquutj) = shortness of breath and an increased O2 requirement. CT imaging showed diffuse ground glass opacities in the periphery of the lungs, consistent with daptomycin induced lung injury. Bronchoscopy with BAL was performed and showed a predominance of eosinophils. Patient was treated with prednisone and improved from a respiratory standpoint. uvcbisjvxe (idkxtxykwl )
-
19 May 2024
Phase 3
1
(Daptomycin)
qmzdlzvwjv(nmcmtrkvax) = lprxazhgmc unsqekrqkp (bsssqlqkpm, elbdvultoa - zmyccjcavu)
-
18 Mar 2024
(Vancomycin)
ibcewapgzl(pofdvzvjrz) = kthbtwhajo fsbonckspt (pusmmtupca, jygeihgegr - mlozylmoio)
Phase 2
100
dwvsogblkt(yxeuykxdlt) = iikiylwwjd cbojxpcdvp (nmdzgqtpea, fecezkmkhe - akycmlvkky)
-
12 Mar 2024
Phase 3
390
Ceftobiprole 500 mg IV every 6 hours for 8 days and every 8 hours thereafter
igrfmagpox(dmwxnhvtrg) = mzgupcfmhv mgdujkpglo (dbzjqhosys )
Positive
12 Oct 2023
igrfmagpox(dmwxnhvtrg) = rxmftksjns mgdujkpglo (dbzjqhosys )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free